Cargando…
Allogeneic Hematopoietic Stem Cell Transplantation After Prior Lung Transplantation for Hereditary Pulmonary Alveolar Proteinosis: A Case Report
Pulmonary alveolar proteinosis (PAP) is a rare, diffuse lung disorder characterized by surfactant accumulation in the small airways due to defective clearance by alveolar macrophages, resulting in impaired gas exchange. Whole lung lavage is the current standard of care treatment for PAP. Lung transp...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344132/ https://www.ncbi.nlm.nih.gov/pubmed/35928826 http://dx.doi.org/10.3389/fimmu.2022.931153 |
_version_ | 1784761151006965760 |
---|---|
author | Beeckmans, Hanne Ambrocio, Gene P. L. Bos, Saskia Vermaut, Astrid Geudens, Vincent Vanstapel, Arno Vanaudenaerde, Bart M. De Baets, Frans Malfait, Thomas L. A. Emonds, Marie-Paule Van Raemdonck, Dirk E. Schoemans, Hélène M. Vos, Robin |
author_facet | Beeckmans, Hanne Ambrocio, Gene P. L. Bos, Saskia Vermaut, Astrid Geudens, Vincent Vanstapel, Arno Vanaudenaerde, Bart M. De Baets, Frans Malfait, Thomas L. A. Emonds, Marie-Paule Van Raemdonck, Dirk E. Schoemans, Hélène M. Vos, Robin |
author_sort | Beeckmans, Hanne |
collection | PubMed |
description | Pulmonary alveolar proteinosis (PAP) is a rare, diffuse lung disorder characterized by surfactant accumulation in the small airways due to defective clearance by alveolar macrophages, resulting in impaired gas exchange. Whole lung lavage is the current standard of care treatment for PAP. Lung transplantation is an accepted treatment option when whole lung lavage or other experimental treatment options are ineffective, or in case of extensive pulmonary fibrosis secondary to PAP. A disadvantage of lung transplantation is recurrence of PAP in the transplanted lungs, especially in hereditary PAP. The hereditary form of PAP is an ultra-rare condition caused by genetic mutations in genes encoding for the granulocyte macrophage-colony stimulating factor (GM-CSF) receptor, and intrinsically affects bone marrow derived-monocytes, which differentiate into macrophages in the lung. Consequently, these macrophages typically display disrupted GM-CSF receptor-signaling, causing defective surfactant clearance. Bone marrow/hematopoietic stem cell transplantation may potentially reverse the lung disease in hereditary PAP. In patients with hereditary PAP undergoing lung transplantation, post-lung transplant recurrence of PAP may theoretically be averted by subsequent hematopoietic stem cell transplantation, which results in a graft-versus-disease (PAP) effect, and thus could improve long-term outcome. We describe the successful long-term post-transplant outcome of a unique case of end-stage respiratory failure due to hereditary PAP-induced pulmonary fibrosis, successfully treated by bilateral lung transplantation and subsequent allogeneic hematopoietic stem cell transplantation. Our report supports treatment with serial lung and hematopoietic stem cell transplantation to improve quality of life and prolong survival, without PAP recurrence, in selected patients with end-stage hereditary PAP. |
format | Online Article Text |
id | pubmed-9344132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93441322022-08-03 Allogeneic Hematopoietic Stem Cell Transplantation After Prior Lung Transplantation for Hereditary Pulmonary Alveolar Proteinosis: A Case Report Beeckmans, Hanne Ambrocio, Gene P. L. Bos, Saskia Vermaut, Astrid Geudens, Vincent Vanstapel, Arno Vanaudenaerde, Bart M. De Baets, Frans Malfait, Thomas L. A. Emonds, Marie-Paule Van Raemdonck, Dirk E. Schoemans, Hélène M. Vos, Robin Front Immunol Immunology Pulmonary alveolar proteinosis (PAP) is a rare, diffuse lung disorder characterized by surfactant accumulation in the small airways due to defective clearance by alveolar macrophages, resulting in impaired gas exchange. Whole lung lavage is the current standard of care treatment for PAP. Lung transplantation is an accepted treatment option when whole lung lavage or other experimental treatment options are ineffective, or in case of extensive pulmonary fibrosis secondary to PAP. A disadvantage of lung transplantation is recurrence of PAP in the transplanted lungs, especially in hereditary PAP. The hereditary form of PAP is an ultra-rare condition caused by genetic mutations in genes encoding for the granulocyte macrophage-colony stimulating factor (GM-CSF) receptor, and intrinsically affects bone marrow derived-monocytes, which differentiate into macrophages in the lung. Consequently, these macrophages typically display disrupted GM-CSF receptor-signaling, causing defective surfactant clearance. Bone marrow/hematopoietic stem cell transplantation may potentially reverse the lung disease in hereditary PAP. In patients with hereditary PAP undergoing lung transplantation, post-lung transplant recurrence of PAP may theoretically be averted by subsequent hematopoietic stem cell transplantation, which results in a graft-versus-disease (PAP) effect, and thus could improve long-term outcome. We describe the successful long-term post-transplant outcome of a unique case of end-stage respiratory failure due to hereditary PAP-induced pulmonary fibrosis, successfully treated by bilateral lung transplantation and subsequent allogeneic hematopoietic stem cell transplantation. Our report supports treatment with serial lung and hematopoietic stem cell transplantation to improve quality of life and prolong survival, without PAP recurrence, in selected patients with end-stage hereditary PAP. Frontiers Media S.A. 2022-07-14 /pmc/articles/PMC9344132/ /pubmed/35928826 http://dx.doi.org/10.3389/fimmu.2022.931153 Text en Copyright © 2022 Beeckmans, Ambrocio, Bos, Vermaut, Geudens, Vanstapel, Vanaudenaerde, De Baets, Malfait, Emonds, Van Raemdonck, Schoemans, Vos and for the Leuven Lung Transplant Group https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Beeckmans, Hanne Ambrocio, Gene P. L. Bos, Saskia Vermaut, Astrid Geudens, Vincent Vanstapel, Arno Vanaudenaerde, Bart M. De Baets, Frans Malfait, Thomas L. A. Emonds, Marie-Paule Van Raemdonck, Dirk E. Schoemans, Hélène M. Vos, Robin Allogeneic Hematopoietic Stem Cell Transplantation After Prior Lung Transplantation for Hereditary Pulmonary Alveolar Proteinosis: A Case Report |
title | Allogeneic Hematopoietic Stem Cell Transplantation After Prior Lung Transplantation for Hereditary Pulmonary Alveolar Proteinosis: A Case Report |
title_full | Allogeneic Hematopoietic Stem Cell Transplantation After Prior Lung Transplantation for Hereditary Pulmonary Alveolar Proteinosis: A Case Report |
title_fullStr | Allogeneic Hematopoietic Stem Cell Transplantation After Prior Lung Transplantation for Hereditary Pulmonary Alveolar Proteinosis: A Case Report |
title_full_unstemmed | Allogeneic Hematopoietic Stem Cell Transplantation After Prior Lung Transplantation for Hereditary Pulmonary Alveolar Proteinosis: A Case Report |
title_short | Allogeneic Hematopoietic Stem Cell Transplantation After Prior Lung Transplantation for Hereditary Pulmonary Alveolar Proteinosis: A Case Report |
title_sort | allogeneic hematopoietic stem cell transplantation after prior lung transplantation for hereditary pulmonary alveolar proteinosis: a case report |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344132/ https://www.ncbi.nlm.nih.gov/pubmed/35928826 http://dx.doi.org/10.3389/fimmu.2022.931153 |
work_keys_str_mv | AT beeckmanshanne allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT ambrociogenepl allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT bossaskia allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT vermautastrid allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT geudensvincent allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT vanstapelarno allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT vanaudenaerdebartm allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT debaetsfrans allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT malfaitthomasla allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT emondsmariepaule allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT vanraemdonckdirke allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT schoemanshelenem allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport AT vosrobin allogeneichematopoieticstemcelltransplantationafterpriorlungtransplantationforhereditarypulmonaryalveolarproteinosisacasereport |